Drug repurposing against SARS-CoV-1, SARS-CoV-2 and MERS-CoV - Archive ouverte HAL Access content directly
Journal Articles Future Microbiology Year : 2021

Drug repurposing against SARS-CoV-1, SARS-CoV-2 and MERS-CoV

(1, 2) , (2, 3) , (1, 2) , (4) , (1, 2) , (1, 2) , (1, 2)
1
2
3
4

Abstract

Since the beginning of the COVID-19 pandemic, large in silico screening studies and numerous in vitro studies have assessed the antiviral activity of various drugs on SARS-CoV-2. In the context of health emergency, drug repurposing represents the most relevant strategy because of the reduced time for approval by international medicines agencies, the low cost of development and the well-known toxicity profile of such drugs. Herein, we aim to review drugs with in vitro antiviral activity against SARS-CoV-2, combined with molecular docking data and results from preliminary clinical studies. Finally, when considering all these previous findings, as well as the possibility of oral administration, 11 molecules consisting of nelfinavir, favipiravir, azithromycin, clofoctol, clofazimine, ivermectin, nitazoxanide, amodiaquine, heparin, chloroquine and hydroxychloroquine, show an interesting antiviral activity that could be exploited as possible drug candidates for COVID-19 treatment.

Dates and versions

hal-03662935 , version 1 (09-05-2022)

Identifiers

Cite

Sarah Aherfi, Bruno Pradines, Christian Devaux, Stéphane Honore, Philippe Colson, et al.. Drug repurposing against SARS-CoV-1, SARS-CoV-2 and MERS-CoV. Future Microbiology, 2021, 16 (17), pp.1341-1370. ⟨10.2217/fmb-2021-0019⟩. ⟨hal-03662935⟩
4 View
0 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More